Tracer library / [68Ga]Ga-P16-093

[68Ga]Ga-P16-093

Also written as [68Ga]Ga-P16-093; [Ga-68]Ga-P16-093

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: Clinical research
Syntheses indexed: 0

Prostate cancer Renal cell carcinoma Dosimetry and biodistribution studies

What it is

Compound class: Small molecule PSMA-targeting PET radioligand (O-(carboxymethyl)-L-tyrosine scaffold with HBED-CC chelator)
Target / mechanism: Prostate-specific membrane antigen (PSMA) PMID 35349040
Clinical application: Prostate cancer patients, including newly diagnosed primary disease and biochemical recurrence PMID 41366119
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [68Ga]Ga-P16-093, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activityMetal impuritiesGe-68 breakthrough

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Ga-68, generator production assumed (no synthesis data found) -> Ge-68 breakthrough (preliminary); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-P16-093.

Get in touch

Notes

Added from reverse module search (stage 6); 3 article(s) with Ga-68. | Stage 30 (2026-09-18): Stage was 'Phase 2 clinical trial'; normalised to 'Clinical research', original wording kept here.